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Purpose: Major genetic factors for age-related macular degeneration (AMD) have recently been identified as susceptibility
risk factors, underlying the role of the complement pathway in AMD. Our purpose was to analyze the role of the R102G
polymorphism of the complement component (C3) gene in a French population, in a case-control study.
Methods: A total of 1,080 patients with exudative AMD and 406 controls were recruited and genotyped for Y402H of
complement factor H (CFH), rs10490924 of age-related maculopathy susceptibility 2 (ARMS2), and R102G of the C3
gene.
Results: The distribution of the R102G genotypes was significantly different in the AMD patients compared to controls
(p=0.02). The Odds Ratio compared to C/C individuals was 1.4 (95% CI 1.1–1.8) for C/G individuals and 1.4 (95% CI
0.8–2.4) for G/G individuals. In a dominant model, the adjusted Odds Ratio for carriers of the G allele is 1.4 (95% CI 1.0–
1.9; p=0.03).
Conclusions: Our study shows C3 to be a moderate susceptibility gene for exudative AMD in the French population.
Age-related macular degeneration (AMD) is the most
common  cause  of  irreversible  vision  loss  in  the  elderly
population  in  Europe  and  the  United  States  [1,2].
Identification  of  risk  factors  is  of  major  importance  for
understanding the origins of the disorder and for establishing
strategies to prevent AMD. Risk factors for AMD are both
environmental [3-9] and genetic [10-18]. Over the past few
years, several single nucleotide polymorphisms (SNPs) have
been  associated  with  AMD,  including  variants  in  the
complement factor H gene (CFH) and the ARMS2/HTRA1
locus  age-related  maculopathy  susceptibility  2  (ARMS2)
[10-17].  AMD  has  been  also  associated  with  other
polymorphisms  of  the  complement  pathway,  such  as  the
complement factor B gene (CFB), the complement component
2 gene (C2), and the complement component 3 gene (C3)
[19-30]. Their involvement in AMD together with the finding
that  drusen  contain  inflammation  proteins  [31],  strongly
suggest the pathway of inflammation and complement in the
pathophysiology of the disease.
R102G  corresponding  to  the  “fast”  and  “slow”
electrophoretic phenotypes has been associated with AMD in
American, British, Dutch, and German populations [22-29].
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Our  purpose  was  to  analyze  the  association  between  this
polymorphism and exudative AMD in a French population.
METHODS
Patients: A total of 1,080 French AMD patients were recruited
in  four  French  retinal  centers—the  Department  of
Ophthalmology  of  Creteil  in  collaboration  with  center
hospitalier  universitaire  (CHU)  de  Bordeaux,  the  Quinze-
Vingts Hospital, and the Centre of Imaging and Laser of Paris
—between November 2005 and July 2007. Written informed
consent was obtained, as required by the French bioethical
legislation and local ethic committee comité de protection des
personnes  (CPP  Henri  Mondor),  and  approved  by  the
Declaration  of  Helsinki  for  research  involving  human
subjects.
Inclusion criteria of the AMD patients were (1) women
or men aged 55 or older and (2) with exudative AMD in at
least one eye, and (3) no association with other retinal disease
(e.g.,  diabetic  retinopathy,  high  myopia,  or  macular
dystrophies). Patients underwent a complete ophthalmologic
examination,  including  best  corrected  visual  acuity
measurement, fundus examination, and retinal photographs.
Fluorescein angiography (FA; Topcon 50IA camera, Tokyo,
Japan)  and  if  needed  indocyanine  green  angiography
Heidelberg  Retina  Angiograph  (HRA;  Heidelberg
Engineering, Heidelberg, Germany) and Optical Coherence
Tomography (OCTIII Stratus, Carl Zeiss Meditec, Inc., San
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1324Leandro, CA) were performed. During the first visit AMD
phenotypes in both eyes were analyzed independently by each
investigator  (E.H.S.  and  N.L.)  before  genetic  testing,
according to color photographs and fluorescein angiography
(FA)  at  presentation.  When  investigators  disagreed  on  a
particular  clinical  feature,  this  patient  was  excluded  from
further analysis. A questionnaire about medical history was
completed.
Controls: Controls were also recruited in the group of patients
who underwent cataract surgery in our four centers. A total of
406 French women or men over 55 years with a normal fundus
examination and normal aspect of fundus photography were
also recruited at the Department of Ophthalmology of Creteil,
France  between  2002  and  2008.  Information  about  their
medical history, including smoking, was obtained.
Genotyping  methods:  Genomic  DNA  was  extracted
immediately or after one night preservation at 4 °C from 10 ml
blood leukocytes using the reagents from the Illustra Genomic
DNA Extraction kit, BACC2, according to the manufacturer’s
protocol (GE Healthcare, Little Chalfont, Buckimghamshire,
UK). CFH Y402H, ARMS2 rs10490924, and rs2230199:C>G
(C3:R102G)  SNPs  were  genotyped  by  quantitative  PCR
TABLE 1. NON-GENETIC CHARACTERISTICS OF THE AMD PATIENTS AND CONTROLS.
Clinical datas Cases Controls p
n 1080 406
Age, m(sd), years 79.0 (7.4) 67.8 (7.7) <0.0001
Men, n(%) 366 (33.9%) 163 (40.2%) =0.025
Hypertension, n/N (%) 567/1061 (53.4%) 138/404 (34.2%) <0.0001
Smoking, n/N (%) 416/1079 (38.6%) 180/404 (44.6%) =0.036
Diabetes, n/N (%) 104/1072 (9.7%) 19/286 (6.6%) =0.11
Hypercholesterolemia n/N (%) 462/1059 (43.6%) 135/403 (33.5%) =0.0004
BMI, m(sd) 25.5 (4.3) 25.4 (4.3) =0.86
Abbreviations: m(sd) represents means (standard deviation). BMI indicates Body Mass Index, kg/m2.
TABLE 2. GENOTYPE DISTRIBUTIONS OF Y402H OF CFH AND RS10490924 OF ARMS2 AMONG THE AMD PATIENTS AND CONTROLS.
Genotypes Cases Controls Global p values Crude OR CI95%*, p Adjusted OR
CI95%†, p
CFH Y402H (rs1061170)
TT 229 (21.2%) 160 (39.4%) <0.0001 1 (ref) 1 (ref)
TC 551 (51.1) 192 (47.3%)   2.0 [1.6–2.6]
p<0.0001
2.3 [1.7–3.2]
<0.0001
CC 299 (27.7%) 54 (13.3%)   3.9 [2.7–5.5]
p<0.0001
4.5 [2.9–7.0]
<0.0001
ARMS2 (rs10490924)
GG 339 (31.4%) 253 (63.7%) <0.0001 1 (ref) 1 (ref)
GT 507 (46.9%) 129 (32.5%)   2.9 [2.3–3.8]
<0.0001
3.0 [2.2–4.1]
<0.0001
TT 234 (21.7%) 15 (3.8%)   11.6 [6.7–20.1]
<0.0001
13.2 [7.2–24.2]
<0.0001
Abbreviations: OR represents Odds ratio, CI represents Confidence interval. * Non-adjusted OR. † Adjusted for age, gender,
tobacco smoking and hypercholesterolemia.
TABLE 3. GENOTYPE DISTRIBUTIONS OF THE RS2230199 OF THE C3 GENE AMONG AMD PATIENTS AND CONTROLS
Genotypes Cases Controls Global p values OR [CI95%]*, p
n 1080 406    
C3 R102G (rs2230199)
CC 583 (54.0%) 252 (62.1%) 0.02 1 (ref)
CG 434 (40.2%) 135 (33.2%)   1.4 [1.1–1.8] p=0.008
GG 63 (5.8%) 19 (4.7%)   1.4 [0.8–2.4] p=0.19
G allelic frequency 0.26 0.21 0.009  
OR: Odds ratio CI: Confidence interval * Non-adjusted OR.
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1325allelic  discrimination  using  reagents  and  conditions  from
Custom  Taqman  SNP  Genotyping  Assays  (Applied
Biosystems, Pleasanton, CA), using ABI 7900HT (Applied
Biosystems). Five percent of the population was genotyped
for quality control; 100% of these duplicates (C3, CFH and
ARMS2 SNPs) are concordant. The call rate of the result was
controlled by the Hardy–Weinberg Test. All of the SNPs are
in Hardy–Weinberg equilibrium.
Statistical analysis: The Hardy–Weinberg assumption was
assessed  by  the  standard  method  comparing  the  observed
numbers of subjects in different genotype categories with the
expected numbers under Hardy–Weinberg equilibrium for the
estimated  allele  frequency  and  testing  with  a  Pearson
goodness-of-fit chi-square (χ2) with one degree of freedom.
The χ2 test was used to compare allelic and genotype
distributions between cases and controls. Logistic regression
models were used to estimate the Odds Ratio (OR) with the
95% confidence interval (95% CI) for AMD risk. A stepwise
regression method has been used to select covariates (with
p<0.15) of the multiple logistic regression model. The OR was
adjusted  for  age,  gender,  smoking  status,
hypercholesterolemia  status,  and  CFH  and  ARMS2
genotypes. Significance levels were set at p<0.05. Analyses
were performed with the SAS software release 9.01 (SAS
Institute INC, Cary, NC).
RESULTS
The population consisted of 1,080 exudative AMD cases and
406  controls.  The  mean±SD  age  at  AMD  diagnosis  was
79.0±7.4  years.  The  nongenetic  characteristics  of  the
population are shown in Table 1. Cases were significantly
older, were less often men and smokers, but had more often
hypertension  and  hypercholesterolemia  than  controls.
However, on the logistic adjusted model, only age, smoking
status, hypercholesterolemia, and gender remain significantly
different between the two groups. The genotype distributions
of the rs1061170 and rs10490924 SNPs within the CFH and
ARMS2, respectively, are shown in Table 2. The genotypic
distributions  of  the  CFH  Y402H  and  ARMS2  SNPs  were
significantly different between cases and controls (p<0.0001).
The genotype distributions of rs2230199 of the C3 gene
are shown in Table 3. The rs2230199 genotype distributions
of the C3 gene were in accordance with the Hardy–Weinberg
equilibrium (p=0.87 in controls and p=0.13 in cases). The
distribution  of  the  rs2230199  genotypes  was  significantly
different in the AMD patients compared to controls (p=0.02).
Individuals carrying the G allele were at an increased risk of
AMD (ORG/C=1.4 CI 95% 1.1–1.8; and ORG/G=1.4 CI 95%
0.8–2.4). Adjusted ORs are shown in Table 4. ORs were
adjusted  for  age,  gender,  tobacco  smoking,
hypercholesterolemia, and CFH and ARMS2 genotypes. In a
dominant model, carriers of the G allele have an adjusted OR
of 1.4 (CI 95% 1.0–1.9, p=0.03). In an additive model (the
genotype was encoded as 0, 1, or 2, according to the number
of risk alleles), the ORs are: crude OR=1.3 [1.1–1.6]/allele,
p=0.0084 and adjusted OR=1.3 [1.1–1.7]/allele, p=0.04.
The minor allele frequency was significantly higher in
AMD patients than in controls (p=0.009).
DISCUSSION
Here  we  report  the  replication  of  an  association  between
R102G of the C3 gene and exudative AMD in the French
population. The study of rs2230199 R102G instead of other
polymorphisms of the gene (i.e., rs1047286:C>T, C3:L314P)
was based on a previous study reporting rs2230199 strongly
associated  with  AMD  and  on  its  functional  role.  This
polymorphism is reported to have a functional consequence
on the C3 protein. The R102G polymorphism generates the
TABLE 4. ADJUSTED OR FOR AGE, CFH, ARMS2 AND C3 GENE AMONG AMD PATIENTS AND CONTROLS.
Age and genotypes OR [CI95%] p OR p global
Age 1.19 [1.16–1.22] < 0.0001  
CFH Y402H (rs1061170)
TT 1 (ref)   <0.0001
TC 2.4 [1.7–3.4] <0.0001  
CC 4.8 [3.0–7.6] <0.0001  
ARMS2 (rs10490924)
GG 1 (ref)   <0.0001
GT 3.1 [1.2–4.3] <0.0001  
TT 12.9 [7.0–23.8] <0.0001  
C3 R102G (rs2230199)
CC 1 (ref) *   0.096
CG 1.4 [1.0–2.0] * <0.04  
GG 1.4 [0.7–2.8] * <0.33  
Abbreviations: OR represents Odds ratio, CI represents Confidence interval. * Adjusted for age, gender, tobacco smoking,
hypercholesterolemia, CFH, and ARMS2 genotypes.
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1327“fast” and “slow” electrophoretic allotypes of C3 (C3F and
C3S) [32], showing a differential capacity to bind monocyte-
complement receptor C3F [33], which is the risk variant for
AMD, and has been previously reported as associated with
other immune-mediated conditions, such as IgA nephropathy
[34],  systemic  vasculitis  [35],  or  membranoproliferative
glomerulonephritis type II [36].
Prior reports of an association with AMD and R102G of
the C3 gene have been made in American, British, Dutch, and
German populations [22-29]. All published studies about C3
and AMD demonstrate a significant association (Table 5). In
our study the homozygous individuals carrying the at-risk
allele have a lower risk compared to previous publications.
Homozygous  GG  individuals  were  not  significantly
associated  with  a  higher  risk  of  AMD  compared  to  the
heterozygous GC individuals. The GG genotype was present
in only 19 controls, and our findings could be explained by a
lack of statistical power, despite the large series of exudative
AMD patients tested. It is notable that our sample sizes are a
little unbalanced (1,080 cases, 406 controls), which may cause
a large variation and power reduction. Another limitation of
the study is the significant differences between cases and
control  populations  (Table  1).  It  remains  possible  that
demographic differences between the group of patients and
controls might affect the OR observed in our study. However,
logistic  regression  analyses  were  performed  to  adjust  for
selected covariates.
We enrolled exudative forms of AMD because patients
with  neovascular  AMD  are  most  often  referred  to  our
specialized retina departments than atrophic forms of AMD
or  early  and  intermediate  AMD.  The  R102G  of  C3  was
associated with different types of AMD. Yates et al. [22] also
showed  a  significant  association  with  choroidal
neovascularization; for case subjects with only geographic
atrophy, the association was significant in the English group
(p=4.6×10−4) but not in the Scottish group, which had fewer
subjects with geographic atrophy. In contrast Maller et al.
[24] reported no difference in association between exudative
AMD  and  geographic  atrophy  compared  to  controls.
Interestingly, Park et al. [26] on their pooled data sets on Mayo
and  Age-Related  Eye  Disease  Study  (AREDS)  subjects
suggest  that  R102G  of  C3  preferentially  associates  with
advanced AMD subtypes than early AMD. Francis et al. [28]
revealed in the AREDS cohort that R102G is significantly
associated with the progression from early AMD to advanced
AMD,  with  no  predisposition  to  geographic  atrophy  or
neovascular AMD. Scholl et al. [29], analyzing progression
of geographic atrophy and the CFH, ARMS2, and C3 variants,
did  not  report  an  association  with  the  progression  of  the
disease and these variants. Additional studies in prospective
cohorts are needed.
In conclusion, our findings reveal C3 to be a moderate
susceptibility  gene  for  exudative  AMD  in  the  French
population and evidence that the complement pathway has a
key role in AMD. Identification and the knowledge of the risk
factors  and  the  interactions  between  all  these  factors  in
individuals may allow new therapeutic methods.
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